Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.72 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | DPP4 | P27487 | 1/20 | 0.52 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.52 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | EP300 | Q09472 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR1E | P28566 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2977256 | 0.89 | MAPK1 (0.57) | MAPK1CREBBPBRD4DPP4DPP8 | |
| SCHEMBL4712216 | 0.89 | MAPK1 (0.56) | MAPK1CREBBPBRD4DPP4DPP8 | |
| SCHEMBL2975661 | 0.89 | MAPK1 (0.56) | MAPK1CREBBPBRD4DPP4DPP8 | |
| SCHEMBL10095067 | 0.89 | BRD4 (0.67) | MAPK1CREBBPBRD4NPC1EP300 | |
| SCHEMBL1336775 | 0.89 | MAPK1 (0.56) | MAPK1CREBBPBRD4DPP4DPP8 | |
| SCHEMBL10211781 | 0.88 | MAPK1 (0.55) | MAPK1CREBBPBRD4NPC1P2RX7 | |
| SCHEMBL10805635 | 0.84 | MAPK1 (1.00) | MAPK1CREBBPBRD4DPP4DPP8 | |
| SCHEMBL2073836 | 0.83 | MAPK1 (0.49) | MAPK1CREBBPBRD4NPC1HTR1D | |
| SCHEMBL5648235 | 0.83 | MAPK1 (0.80) | MAPK1CREBBPBRD4DPP4DPP8 | |
| SCHEMBL2966970 | 0.83 | MAPK1 (0.49) | MAPK1CREBBPBRD4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008788-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | SUZHOU ARK BIOPHARMACEUTICAL CO LTD (CN) | 2026-01-08 | — | — | US | disclosed |
| EP-4596554-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | Suzhou Arkbiopharmaceutical Co., Ltd. (CN) | 2025-08-06 | — | — | EP | disclosed |
| CN-119698422-A | Aza condensed ring compound, preparation method and medical application thereof | 苏州爱科百发生物医药技术有限公司 | 2025-03-25 | — | — | CN | disclosed |
| WO-2024067660-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | 苏州爱科百发生物医药技术有限公司 | 2024-04-04 | — | — | WO | disclosed |
| EP-1589969-A4 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7265128-B2 | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20060069116-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-03-30 | — | — | US | disclosed |
| EP-1589969-A2 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co. Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004064778-A2 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO. INC. (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008788-A1 | AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | PDE4B, PDE4A, CYP4A11 | MAPK1 2674/4885CREBBP 3257/4885BRD4 1136/4885 |
| US-20060069116-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | MAPK1 3966/4885CREBBP 3217/4885BRD4 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.